Figure 1: High-resolution DNA copy number profiling of human DLBCL.

(a) DNA copy number profiles from 609 primary DLBCL tumours were analysed for significant alterations using the GISTIC algorithm. This algorithm uses the magnitude and frequency of alterations at each position in the genome to assign a GISTIC Q value, with decreasing values indicating increasing significance. Significant peaks (GISTIC Q value <0.10) of DNA copy number loss (blue) and gain (red) are annotated with their genomic location. (b) In 232 patients treated with combination chemotherapy (CHOP) in the absence of Rituximab, presence of 3q27.2 gain (red) was associated with significantly worse overall survival than those with diploid copy number at this region (black). Log-rank P-value=0.004. (c) Gain of 3q27.2 (red) remained to be associated with significantly worse overall survival compared with diploid 3q27.2 (black) in 196 patients treated with combination chemotherapy plus Rituximab (R-CHOP). Log-rank P-value=0.001. (d) For 249 cases with matched gene expression profiling data, tumours were classified into GCB-like (orange) and ABC-like subtypes (blue) based upon the Wright 140 gene algorithm (heatmap shown). Gain of 3q27.2, shown by red tick marks for each case in which it was detected, was significantly over-represented in the ABC-like subtype compared with the GCB-like subtype (Fisher P value ≤0.001).